The Effect of Milnacipran in Patients With Fibromyalgia

• Status: Completed
• Trial end date: 2014-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Use of the drug Milnacipran will reduce ventricular lactate levels and processing time for completing complex tasks relative to placebo.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Beth Israel Medical Center
• Treatments: Levomilnacipran; Milnacipran

Criteria

Inclusion Criteria:

• Female or male subjects who fulfill the American College of Rheumatology's case definition for Fibromyalgia.

• 18 through 68 years of age

Exclusion Criteria:

• Pregnant or trying to become pregnant

• Taking any other Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or already taking milnacipran

• Patients who do not indicate their pain levels as less than substantial despite their best care

• History of any psychotic disorder or history of alcoholism or drug abuse within 10 years of intake as determined by psychiatric diagnostic interview

• Presence of current depression as determined by psychiatric diagnostic interview

• Presence of brain lesion on MRI anatomical study